Biotech · Public company · Dallas, TX, US

Taysha Gene Therapies, Inc.

Ticker TSHA · SEC CIK 0001806310

Track this companyFree. Adds Taysha Gene Therapies, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials43 recruiting or active

Pipeline programs2From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline2

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett SyndromePHASE3 · ACTIVE_NOT_RECRUITING · started May 8, 2026ClinicalTrials.gov NCT07480564 · fetched Nov 12, 2026
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 12, 2023ClinicalTrials.gov NCT06152237 · fetched Nov 12, 2026
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 6, 2023ClinicalTrials.gov NCT05606614 · fetched Nov 12, 2026
A Study of the Natural Course of SURF1 DeficiencyWITHDRAWN · started May 4, 2022ClinicalTrials.gov NCT05277363 · fetched Nov 12, 2026